Why SoundHound AI (SOUN) Is Up 16.1% After Casey’s Expands Voice Ordering Partnership Across 2,600 Stores

SoundHound AI

SoundHound AI

SOUN

0.00

  • In April 2026, SoundHound AI announced that Casey’s renewed and expanded their long-standing partnership, rolling out SoundHound’s voice AI ordering agents across more than 2,600 stores after handling over 21 million guest interactions and millions of food orders.
  • This deepening collaboration highlights how enterprise customers are operationalizing voice AI at scale, using automated ordering to reduce missed calls, streamline kitchens, and free staff for in-store service.
  • Next, we’ll examine how this expanded Casey’s rollout could influence SoundHound AI’s investment narrative around scaling agentic voice AI partnerships.

Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

SoundHound AI Investment Narrative Recap

To own SoundHound AI, you need to believe that agentic voice AI can become a must-have automation layer for restaurants, automotive, and broader enterprise, and that this will eventually support a path toward profitability despite ongoing losses and lumpy large contracts. The expanded Casey’s rollout reinforces the near term catalyst around scaling real world deployments, but it does not remove the key risk that rising costs and uneven deal timing keep earnings volatile.

Among recent developments, the planned acquisition of LivePerson stands out alongside the Casey’s news. While Casey’s showcases high volume voice ordering in thousands of locations, LivePerson adds a large base of messaging centric enterprise customers. Together, they speak directly to the catalyst of broader conversational AI adoption across channels, while also raising fair questions about whether acquisitions and heavier spending ultimately translate into sustainable margins and more predictable revenue.

Yet behind the excitement around Casey’s and LivePerson, investors should be aware that rising operating losses and deal concentration risk could still...

SoundHound AI's narrative projects $264.9 million revenue and $30.2 million earnings by 2029. This requires 16.2% yearly revenue growth and a $44.2 million earnings increase from -$14.0 million today.

Uncover how SoundHound AI's forecasts yield a $14.62 fair value, a 54% upside to its current price.

Exploring Other Perspectives

SOUN 1-Year Stock Price Chart
SOUN 1-Year Stock Price Chart

Lowest estimate analysts sound far more cautious, even before this Casey’s expansion, assuming about US$305.9 million revenue and only US$40.0 million earnings by 2028, so you should expect a much wider range of opinions on how risks like commoditized voice tech and rising regulation could reshape SoundHound’s story from here.

Explore 9 other fair value estimates on SoundHound AI - why the stock might be worth just $9.50!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your SoundHound AI research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
  • Our free SoundHound AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate SoundHound AI's overall financial health at a glance.

Searching For A Fresh Perspective?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

  • Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
  • Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
  • AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.